TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35584876

Group type: EXPERIMENTAL
Intervention: Symptomatic individuals
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Low oxygen levels on enrolment
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: More than one chronic comorbidity
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Older age, low oxygen level, respiratory symptoms, chronic comorbidities
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 751
Study: 35584875

Group type: EXPERIMENTAL
Intervention: COVID-19 hospitalised individuals
Number of subjects: 149
Study: 35584910

Group type: EXPERIMENTAL
Intervention: Thrombectomy for emergent large vessel occlusion
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Older patients with a history of diabetes or hypertension, elevated pretreatment SBP, and failed reperfusion
Number of subjects: 270
Study: 35585125

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 109

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 109
Study: 35585554

Group type: EXPERIMENTAL
Intervention: Moderate calorie intake (10-20 kcal/kg)
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Moderate protein intake (0.8-1.2 g/kg)
Number of subjects: 1172

Group type: COMPARATOR
Intervention: Low calorie intake (< 10 kcal/kg)
Number of subjects: 1172

Group type: COMPARATOR
Intervention: Low protein intake (< 0.8 g/kg)
Number of subjects: 1172

Group type: COMPARATOR
Intervention: High calorie intake (> 20 kcal/kg)
Number of subjects: 1172

Group type: COMPARATOR
Intervention: High protein intake (> 1.2 g/kg)
Number of subjects: 1172
Study: 35585684

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (unvaccinated)
Number of subjects: 0
Study: 35585781

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients (betaine)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients (TMAO)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Post-liver transplantation (betaine)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Post-liver transplantation (TMAO)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients (CPT stage and MELD score)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients (TMAO and MELD score)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients (mortality)
Number of subjects: 129
Study: 35585867

Group type: EXPERIMENTAL
Intervention: Transcranial Electromagnetic Treatment (TEMT)
Number of subjects: 8
Study: 35587165

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 0
Study: 35587172

Group type: COMPARATOR
Intervention: Topical clonidine (TC) 0.1% or 0.2% applied in gel form to the painful area two to three times daily for 8 to 12 weeks.
Number of subjects: 743
Study: 35587370

Group type: COMPARATOR
Intervention: Standard PrEP counseling (Control)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: MES-PrEP and standard PrEP counseling
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Enhanced YaCool and standard PrEP counseling
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: MES-PrEP, Enhanced YaCool, and standard PrEP counseling
Number of subjects: 160
Study: 35587408

Group type: EXPERIMENTAL
Intervention: Adolescent Identity Treatment (AIT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dialectical Behavior Therapy for Adolescents (DBT-A)
Number of subjects: 60
Study: 35587446

Group type: EXPERIMENTAL
Intervention: binimetinib plus ribociclib
Number of subjects: 0
Study: 35587487

Group type: EXPERIMENTAL
Intervention: Everolimus (4.5 mg/m2 daily for 7 days)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 14
Study: 35587536

Group type: EXPERIMENTAL
Intervention: Prophylactic-dose subcutaneous enoxaparin (40 mg once daily) for 6 months after 3 months of therapeutic-dose LMWH.
Number of subjects: 52
Study: 35587650

Group type: EXPERIMENTAL
Intervention: Relugolix (by mouth once daily)
Number of subjects: 930

Group type: COMPARATOR
Intervention: Leuprolide (injected every 3 months)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Relugolix
Number of subjects: 930

Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 930
Study: 35587832

Group type: EXPERIMENTAL
Intervention: Peer-to-peer training and follow-up academic detailing including overdose prevention education and buprenorphine prescribing.
Number of subjects: 122
Study: 35588104

Group type: EXPERIMENTAL
Intervention: Glabellar onabotulinumtoxinA injections
Number of subjects: 9
Study: 35588166

Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics (AB+)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Food allergy
Number of subjects: 436

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 436
Study: 35588252

Group type: EXPERIMENTAL
Intervention: Prehabilitation (four-week trimodal programme: exercise, nutritional intervention, anxiety reduction)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 250
Study: 35588274

Group type: EXPERIMENTAL
Intervention: Modified fluid gelatin 4% in a balanced electrolyte solution
Number of subjects: 221

Group type: COMPARATOR
Intervention: Albumin (50 g L)
Number of subjects: 221
Study: 35588317

Group type: EXPERIMENTAL
Intervention: Idursulfase-IT 10 mg or 30 mg administered monthly via IT drug delivery device or lumbar puncture
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Idursulfase-IT treatment
Number of subjects: 15
Study: 35588372

Group type: EXPERIMENTAL
Intervention: Incidence of AKI within 72 hours after surgery according to KDIGO criteria
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Use of renal replacement therapy (RRT)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Mortality during ICU and hospital stay
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Length of ICU and hospital stay
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Major adverse kidney events (persistent renal dysfunction, RRT, and mortality) at day 90
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Urinary biomarkers for early detection of AKI
Number of subjects: 10000
Study: 35588692

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W for 35 cycles (2 years)
Number of subjects: 351
Study: 35588734

Group type: EXPERIMENTAL
Intervention: TNF-α intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35588752

Group type: EXPERIMENTAL
Intervention: Tazemetostat 800 mg once on day 1 and then twice daily from day 2 onwards (part 1); Tazemetostat 800 mg twice daily starting on day 1 of cycle 1 (part 2)
Number of subjects: 74
Study: 35589029

Group type: EXPERIMENTAL
Intervention: Transfemoral carotid artery stenting (TF-CAS)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 376
Study: 35589078

Group type: EXPERIMENTAL
Intervention: Port Delivery System with ranibizumab (PDS)
Number of subjects: 0
Study: 35589164

Group type: EXPERIMENTAL
Intervention: Previous statin therapy
Number of subjects: 14542
Study: 35589172

Group type: EXPERIMENTAL
Intervention: Local Impedance (LI) drop during pulmonary vein isolation (PVI)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Optimal LI drops identified by left atrial region
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Starting LI before radiofrequency (RF) application
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Local Impedance (LI) drop
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Preablation starting LI
Number of subjects: 58
Study: 35589234

Group type: EXPERIMENTAL
Intervention: Low FFR/low CFR
Number of subjects: 2143

Group type: EXPERIMENTAL
Intervention: Low FFR/normal CFR
Number of subjects: 2143

Group type: EXPERIMENTAL
Intervention: Normal FFR/low CFR
Number of subjects: 2143

Group type: COMPARATOR
Intervention: Normal FFR/normal CFR
Number of subjects: 2143

Group type: COMPARATOR
Intervention: Revascularized vessels
Number of subjects: 2143
Study: 35589352

Group type: EXPERIMENTAL
Intervention: Dolutegravir/lamivudine dual antiretroviral therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other dual-drug and three-drug combinations
Number of subjects: 0
Study: 35589363

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Number of subjects: 712
Study: 35589542

Group type: EXPERIMENTAL
Intervention: BNT162b2 COVID-19 vaccine, 2 doses
Number of subjects: 150

Group type: COMPARATOR
Intervention: Unvaccinated patients
Number of subjects: 150
Study: 35589711

Group type: EXPERIMENTAL
Intervention: Antisense oligonucleotide (ASO) targeting the aberrant C9ORF72 transcript
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 35589962

Group type: EXPERIMENTAL
Intervention: In-utero co-exposure to Hg, Pb, and Cd
Number of subjects: 1442

Group type: EXPERIMENTAL
Intervention: Adequate maternal micronutrients (selenium and folate)
Number of subjects: 1442
Study: 35589975

Group type: EXPERIMENTAL
Intervention: COVID-19 critical care professionals
Number of subjects: 1372

Group type: EXPERIMENTAL
Intervention: COVID-19 patients or those with doubts about infection
Number of subjects: 1372

Group type: EXPERIMENTAL
Intervention: Peak incidence moments
Number of subjects: 1372
Study: 35590038

Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 315
Study: 35590143

Group type: EXPERIMENTAL
Intervention: JAK1 inhibitor itacitinib
Number of subjects: 1
Study: 35591977

Group type: EXPERIMENTAL
Intervention: IV etoposide 100 mg/m²
Number of subjects: 25
Study: 35592378

Group type: COMPARATOR
Intervention: Modest COVID-19 restrictions (June 9 to October 18, 2020)
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Strong COVID-19 restrictions (October 19, 2020, to April 17, 2021)
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Strong COVID-19 restrictions
Number of subjects: 873
Study: 35592490

Group type: COMPARATOR
Intervention: Duloxetine (10-week treatment)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Desvenlafaxine (12-week treatment)
Number of subjects: 34
Study: 35592513

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation ≥1000 IU/day
Number of subjects: 637

Group type: COMPARATOR
Intervention: Vitamin D supplementation 200 IU/day
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Achieved 25(OH)D concentrations ≥40 ng/mL
Number of subjects: 637
Study: 35593638

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35593967

Group type: EXPERIMENTAL
Intervention: Continuous wireless monitoring of vital signs (peripheral oxygen saturation, heart rate, respiratory rate) and non-invasive blood pressure measured every 30-60 min
Number of subjects: 200
Study: 35594123

Group type: EXPERIMENTAL
Intervention: Topiramate (100 mg/day, 200 mg/day, 400 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Baseline serum etonogestrel concentrations
Number of subjects: 48
Study: 35594464

Group type: EXPERIMENTAL
Intervention: Oncofertility counseling offered at the time of diagnosis
Number of subjects: 0
Study: 35595203

Group type: EXPERIMENTAL
Intervention: Improvement in cardiac damage stage post-AVR
Number of subjects: 1974

Group type: EXPERIMENTAL
Intervention: No change in cardiac damage stage post-AVR
Number of subjects: 1974

Group type: EXPERIMENTAL
Intervention: Worsening of cardiac damage stage post-AVR
Number of subjects: 1974
Study: 35595320

Group type: EXPERIMENTAL
Intervention: Increased frequencies of IgA in patients with severe asthma
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Memory B-cells in severe asthma patients
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Immature B-cell populations in severe asthma patients
Number of subjects: 154
Study: 35595617

Group type: EXPERIMENTAL
Intervention: SN-5 questionnaire after 4-week treatment
Number of subjects: 116

Group type: COMPARATOR
Intervention: SN-5 questionnaire
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: SN-5 scores
Number of subjects: 116
Study: 35595730

Group type: EXPERIMENTAL
Intervention: Pirtobrutinib (LOXO-305), a reversible inhibitor of Bruton's tyrosine kinase (BTK)
Number of subjects: 0
Study: 35596173

Group type: EXPERIMENTAL
Intervention: Euglycaemic clamp followed by hypoglycaemic clamp
Number of subjects: 14
Study: 35596181

Group type: EXPERIMENTAL
Intervention: Camrelizumab (60mg, 200mg, 400mg)
Number of subjects: 36
Study: 35596592

Group type: EXPERIMENTAL
Intervention: Unilateral hypoglossal nerve stimulation
Number of subjects: 29
Study: 35596679

Group type: EXPERIMENTAL
Intervention: Downregulated pro-inflammatory complement factor D (CFD)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Proteomic profiling
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Inflammatory protein CFD and serpin family B member 1
Number of subjects: 28
Study: 35596791

Group type: EXPERIMENTAL
Intervention: MK-4621 monotherapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MK-4621 plus pembrolizumab
Number of subjects: 45

Group type: COMPARATOR
Intervention: MK-4621 monotherapy and MK-4621 plus pembrolizumab
Number of subjects: 45
Study: 35596885

Group type: EXPERIMENTAL
Intervention: Patients with comorbidities
Number of subjects: 2813

Group type: COMPARATOR
Intervention: Patients without comorbidities
Number of subjects: 2813
Study: 35597052

Group type: EXPERIMENTAL
Intervention: Visible objects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Occluded objects
Number of subjects: 0
Study: 35597752

Group type: EXPERIMENTAL
Intervention: LV20.19 CAR T cells
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Stimulation with CD19 or CD20 antigens
Number of subjects: 15
Study: 35597904

Group type: EXPERIMENTAL
Intervention: Volasertib (250-350 mg on D1 and D15)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Volasertib monotherapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Volasertib with azacitidine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 22
Study: 35598186

Group type: EXPERIMENTAL
Intervention: vemurafenib/cobimetinib administered via feeding tube
Number of subjects: 2
Study: 35598313

Group type: EXPERIMENTAL
Intervention: PVI + PWI radio frequency ablation (RFA)
Number of subjects: 24
Study: 35598394

Group type: EXPERIMENTAL
Intervention: Apilimod
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Berbamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cepharanthine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (S)-crizotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delta and Omicron variants
Number of subjects: 0
Study: 35598419

Group type: EXPERIMENTAL
Intervention: Right hemisphere subthalamic nucleus deep brain stimulation (DBS) for Parkinson's disease
Number of subjects: 0
Study: 35598441

Group type: EXPERIMENTAL
Intervention: SJ733 (300 mg daily for 3 days)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: SJ733 (600 mg daily for 3 days)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: SJ733 (75 mg single dose) + cobicistat (150 mg single dose)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: SJ733 (300 mg single dose) + cobicistat (150 mg single dose)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: SJ733 (600 mg single dose) + cobicistat (150 mg single dose)
Number of subjects: 27

Group type: COMPARATOR
Intervention: SJ733 (600 mg single dose) ± cobicistat
Number of subjects: 27
Study: 35598589

Group type: EXPERIMENTAL
Intervention: Maintaining WAZ > 0
Number of subjects: 178

Group type: COMPARATOR
Intervention: Stable around WAZ = 0
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Partially recovered
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Never recovered
Number of subjects: 178
Study: 35598604

Group type: EXPERIMENTAL
Intervention: BBM-H901 (5 × 10^13 vg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: BBM-H901
Number of subjects: 10
Study: 35598718

Group type: EXPERIMENTAL
Intervention: Passive eating monitoring via wrist-worn device measuring bites, eating duration, and eating rate
Number of subjects: 25
Study: 35599187

Group type: EXPERIMENTAL
Intervention: Etoposide-cisplatin (EP) followed by carboplatin (CARBO)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Etoposide-cisplatin (EP)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Carboplatin (CARBO)
Number of subjects: 102
Study: 35599248

Group type: EXPERIMENTAL
Intervention: CytoSorb
Number of subjects: 20
Study: 35599261

Group type: EXPERIMENTAL
Intervention: Overfeeding for 8 weeks
Number of subjects: 22
Study: 35599302

Group type: EXPERIMENTAL
Intervention: IDH1-vac
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: IDH1-vac + AVE
Number of subjects: 48

Group type: COMPARATOR
Intervention: AVE only
Number of subjects: 48
Study: 35599306

Group type: EXPERIMENTAL
Intervention: De novo PEG-IFN therapy
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Add-on PEG-IFN therapy
Number of subjects: 390

Group type: COMPARATOR
Intervention: Anti-HBc levels
Number of subjects: 390
Study: 35599315

Group type: EXPERIMENTAL
Intervention: Low-energy diet (LED)
Number of subjects: 211
Study: 35599349

Group type: EXPERIMENTAL
Intervention: Activity paradigm (M = 4.11; SD = 0.78)
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Rest paradigm (M = 2.56; SD = 0.78)
Number of subjects: 1244
Study: 35599736

Group type: EXPERIMENTAL
Intervention: CCFES plus cHMC rTMS
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: CCFES plus iM1 rTMS
Number of subjects: 72

Group type: COMPARATOR
Intervention: CCFES plus sham rTMS
Number of subjects: 72
Study: 35599977

Group type: EXPERIMENTAL
Intervention: Acute stress symptoms assessment through interviews conducted by child and adolescent psychologists and psychiatrists from day 1 to day 3 post-storm.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Children aged 0-5 years
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Children aged 6-11 years
Number of subjects: 116
Study: 35600486

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg Q2W plus statin therapy (atorvastatin 20 mg/day or rosuvastatin 10 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard statin therapy
Number of subjects: 0
Study: 35601412

Group type: EXPERIMENTAL
Intervention: HMO supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35602004

Group type: EXPERIMENTAL
Intervention: Nanocovax vaccine (25 mcg, 50 mcg, and 75 mcg doses with 0.5 mg aluminium hydroxide adjuvant)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo (0.5 mg aluminium hydroxide adjuvant only)
Number of subjects: 560
Study: 35602475

Group type: EXPERIMENTAL
Intervention: Combination of clindamycin and low dose TMP/SMX (CT group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard dose of TMP/SMX (T group)
Number of subjects: 20
Study: 35602489

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 120
Study: 35603037

Group type: EXPERIMENTAL
Intervention: CEASE intervention
Number of subjects: 11
Study: 35603165

Group type: EXPERIMENTAL
Intervention: EGFRvIII-directed CAR T cell therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35603278

Group type: EXPERIMENTAL
Intervention: Bispecific LV20.19 CAR T cell therapy
Number of subjects: 15
Study: 35603289

Group type: EXPERIMENTAL
Intervention: Powered elbow-wrist-hand orthosis using BCI
Number of subjects: 1

Group type: COMPARATOR
Intervention: Myoelectric control
Number of subjects: 1

Group type: COMPARATOR
Intervention: No device
Number of subjects: 1
Study: 35603302

Group type: EXPERIMENTAL
Intervention: Auditory slow wave stimulation for two weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation for two weeks
Number of subjects: 16
Study: 35603455

Group type: EXPERIMENTAL
Intervention: Circulating microRNA profiles
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Plasma miRNA profiling using RT-qPCR
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Complete pulmonary evaluation and chest computed tomography
Number of subjects: 200
Study: 35603508

Group type: EXPERIMENTAL
Intervention: Circulating miRNAs (miR-486-3p, miR-103a-3p, miR-106b-3p, miR-182-5p, miR-101-3p, miR-10a-5p, miR-125a-5p, miR-146b-5p, miR-26a-5p, miR-423-5p, miR-92b-3p)
Number of subjects: 5
Study: 35603665

Group type: EXPERIMENTAL
Intervention: Health status trajectories before and after hospitalization for heart failure
Number of subjects: 0
Study: 35603667

Group type: EXPERIMENTAL
Intervention: Combination medical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35603905

Group type: EXPERIMENTAL
Intervention: Neoadjuvant/induction platinum-based combination chemotherapy (NAIC)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Combination immune checkpoint inhibition (cICI)
Number of subjects: 107
Study: 35604152

Group type: COMPARATOR
Intervention: Placebo and psychologic intervention
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo and general education
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Propranolol and psychologic intervention
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Propranolol and general education
Number of subjects: 261
Study: 35604203

Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine
Number of subjects: 83
Study: 35604212

Group type: EXPERIMENTAL
Intervention: Dolutegravir coadministered with rifampicin
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Alternative dolutegravir dosing regimens
Number of subjects: 41
Study: 35604343

Group type: EXPERIMENTAL
Intervention: MLC601/MLC901 for 6 months in addition to standard care and rehabilitation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care and rehabilitation
Number of subjects: 30
Study: 35604701

Group type: EXPERIMENTAL
Intervention: Struggling profile (n = 83; 45%)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Coping profile (n = 41; 22%)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Coping but concerned profile (n = 62; 33%)
Number of subjects: 186
Study: 35604723

Group type: EXPERIMENTAL
Intervention: Telehealth mental health screening using PHQ-9 and GAD-7
Number of subjects: 0
Study: 35604754

Group type: EXPERIMENTAL
Intervention: Comprehensive travel health education
Number of subjects: 152

Group type: COMPARATOR
Intervention: No specific intervention (Control)
Number of subjects: 152
Study: 35604758

Group type: EXPERIMENTAL
Intervention: 38% Silver Diamine Fluoride (SDF)
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: 5% Sodium Fluoride (NaF) varnish
Number of subjects: 791

Group type: COMPARATOR
Intervention: Placebo control (tonic water)
Number of subjects: 791